^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

2189 Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation

Published date:
11/04/2020
Excerpt:
We retrospectively reviewed pts with CMML, both with and without BT, treated with VEN-based therapy…NPM1 mutations predict for CR and RUNX1 mutations are associated with a trend to higher ORR.